Gynecomastia is listed as a rare side effect of numerous antihypertensive medications (Table). It occurs in

THE JOURNAL OF CLINICAL HYPERTENSION VOL. VI NO. VIII AUGUST 2004470

antagonist that is not associated with endocrine side effects, spironolactone should still be the aldosterone antagonist of first choice for the treatment of heart failure or hypertension because it has well document-ed efficacy and is less costly. Nevertheless, if gyne-comastia or other troubling endocrine side effects develop with the use of spironolactone, eplerenone would be an appropriate substitute.

The Journal of Clinical Hypertension (ISSN 1524-6175) is published monthly by Le Jacq Communications, Inc., Three Parklands Drive, Darien, CT 06820-3652. Copyright 2004 by Le Jacq Communications, Inc., All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publishers. The opinions and ideas expressed in this publication are those of the authors and do not necessarily reflect those of the Editors or Publisher. For copies in excess of 25 or for commercial purposes, please contact Sarah Howell at showell@lejacq.com or 203.656.1711 x106.